<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923962</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1 Coronary circulation 01</org_study_id>
    <nct_id>NCT00923962</nct_id>
  </id_info>
  <brief_title>Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Endothelial and Metabolic Effects of GLP-1 in Coronary Circulation in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GLP-1 is an incretin hormone which is discharged from the intestines after food intake. The
      hormone is known for its powerful insulinotropic and trophic effects on the beta cells in the
      pancreas and is currently used as an anti-diabetic agent in patients with type 2 diabetes
      (T2DM).

      GLP-1 receptors are widely distributed including on the endothelial cells in both coronary
      and skeletal muscle circulation and on the myocardium. GLP-1-receptor studies on knock-out
      mice have shown that they exhibit a reduced myocardial contractility and reduced diastolic
      heart function. GLP-1 also shows beneficial cardiovascular effects in patients with acute
      myocardial infarctions and dogs with dilated cardiomyopathy in that the left ventricle
      function and endothelial dysfunction improves after GLP-1 treatment via insulin-independent
      mechanisms. Preclinical studies indicate that exogenous administrated GLP-1 in physiological
      concentrations can improve perfusion but this has never been tested in humans. It is also
      unknown whether GLP-1 can directly increase the glucose/metabolite uptake across both cardiac
      and skeletal muscle in an insulin independent manner. Unpublished studies do however indicate
      that the improvement in the cardiovascular system is largely dependent upon a high blood
      glucose level and only partially dependent upon the antiglycemic effects of GLP-1.

      In the proposed studies the investigators wish to examine the physiological role of GLP-1
      receptor stimulation both with regard to perfusion, metabolic improvement as well as cardiac
      inotropic. These studies will be conducted in both healthy and in T2DM patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary blood flow</measure>
    <time_frame>10 minutes after I.A. GLP-1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary metabolite uptake</measure>
    <time_frame>10 minutes after I.A. GLP-1</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Artherosclerosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon like peptide-1</intervention_name>
    <description>0,1 pmol/kg/min</description>
    <arm_group_label>Type 2 Diabetes patients</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Artherosclerosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>20-40 microgram/minute</description>
    <arm_group_label>Type 2 Diabetes patients</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Artherosclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians over 18

          -  Emitted for non-acute coronary arteriography (CAG) in Gentofte hospital

          -  BMI 23-35 kg/m2

          -  Normal hemoglobin

          -  Who gives informed consent

          -  Those with type 2 diabetes: HbA1c 6-10%

          -  Those without type 2 diabetes: Normal oral glucose tolerance test (OGTT) according to
             WHO criteria

        Exclusion Criteria:

          -  Liver disease (ALAT &gt; 2x normal)

          -  Diabetic nefropati (Creatinine &gt; 130 µM or albuminuria)

          -  Treatment with medicine that cannot be paused 12 hours before intervention

          -  Pregnancy or breastfeeding

          -  Insulin- or glitazone treatment

          -  Healthy controls: close family history with diabetes

          -  Unstable angina pectoris

          -  Non-STEMI

          -  Atrial fibrillation

          -  Valvular disease

          -  LVEF &lt; 50%

          -  Severe systemic disease

          -  Type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan S Jensen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>University hospital Gentofte, Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaya Rosenmeier, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Gentofte, Department of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gentofte, Department of Cardiology</name>
      <address>
        <city>Gentofte</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Bjällmark A, Larsson M, Winter R, Westholm C, Jacobsen P, Lind B, Brodin LA. Velocity tracking--a novel method for quantitative analysis of longitudinal myocardial function. J Am Soc Echocardiogr. 2007 Jul;20(7):847-56.</citation>
    <PMID>17617311</PMID>
  </reference>
  <reference>
    <citation>Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003 Jul 16;42(2):328-35.</citation>
    <PMID>12875772</PMID>
  </reference>
  <reference>
    <citation>Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999 Jan;48(1):86-93.</citation>
    <PMID>9892226</PMID>
  </reference>
  <reference>
    <citation>Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001 Dec 15;102(2-3):81-6.</citation>
    <PMID>11730979</PMID>
  </reference>
  <reference>
    <citation>Luque MA, González N, Márquez L, Acitores A, Redondo A, Morales M, Valverde I, Villanueva-Peñacarrillo ML. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol. 2002 Jun;173(3):465-73.</citation>
    <PMID>12065236</PMID>
  </reference>
  <reference>
    <citation>Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Schnohr P, Jensen JS. Tissue Doppler echocardiography in persons with hypertension, diabetes, or ischaemic heart disease: the Copenhagen City Heart Study. Eur Heart J. 2009 Mar;30(6):731-9. doi: 10.1093/eurheartj/ehn596. Epub 2009 Jan 27.</citation>
    <PMID>19176536</PMID>
  </reference>
  <reference>
    <citation>Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001 Sep;24(9):1614-9.</citation>
    <PMID>11522708</PMID>
  </reference>
  <reference>
    <citation>Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004 Mar 2;109(8):962-5. Epub 2004 Feb 23.</citation>
    <PMID>14981009</PMID>
  </reference>
  <reference>
    <citation>Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003 Jun;21(6):1125-35.</citation>
    <PMID>12777949</PMID>
  </reference>
  <reference>
    <citation>Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1209-15. Epub 2004 Sep 7.</citation>
    <PMID>15353407</PMID>
  </reference>
  <reference>
    <citation>Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996 Jul;137(7):2968-78.</citation>
    <PMID>8770921</PMID>
  </reference>
  <reference>
    <citation>Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995 Jan 30;358(3):219-24.</citation>
    <PMID>7843404</PMID>
  </reference>
  <reference>
    <citation>Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand. 1996 Jul;157(3):355-7. Review.</citation>
    <PMID>8830893</PMID>
  </reference>
  <reference>
    <citation>Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2401-8. Epub 2005 Jul 15.</citation>
    <PMID>16024574</PMID>
  </reference>
  <reference>
    <citation>Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008 May 6;117(18):2340-50. doi: 10.1161/CIRCULATIONAHA.107.739938. Epub 2008 Apr 21. Erratum in: Circulation. 2008 Jul 22;118(4):e81.</citation>
    <PMID>18427132</PMID>
  </reference>
  <reference>
    <citation>Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005 Feb 15;125(1-3):173-7.</citation>
    <PMID>15582729</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>September 17, 2012</last_update_submitted>
  <last_update_submitted_qc>September 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Jacob Christian Sivertsen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Basic science</keyword>
  <keyword>Type 2 Diabetes mellitus</keyword>
  <keyword>Glucagon like peptid-1</keyword>
  <keyword>Coronary Bloodflow</keyword>
  <keyword>Metabolite uptake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

